Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    CheckMate 172
Previous Study | Return to List | Next Study

A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02156804
Recruitment Status : Active, not recruiting
First Posted : June 5, 2014
Last Update Posted : July 13, 2018
Sponsor:
Information provided by (Responsible Party):
Bristol-Myers Squibb

Brief Summary:
The purpose of this study is to determine the rate and frequency of high-grade (CTCAE v4.0 Grade 3 or higher), treatment-related, select adverse events in subjects with histologically confirmed stage III (unresectable) or stage IV melanoma and progression post prior treatment containing an anti-Cytotoxic T Lymphocyte Antigen (CTLA-4) monoclonal antibody, treated with Nivolumab (BMS-936558) at a dose of 3 mg/kg every two weeks.

Condition or disease Intervention/treatment Phase
Melanoma Drug: Nivolumab (BMS-936558) Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1215 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody
Actual Study Start Date : October 7, 2014
Estimated Primary Completion Date : January 30, 2019
Estimated Study Completion Date : January 30, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Melanoma
Drug Information available for: Nivolumab

Arm Intervention/treatment
Experimental: Nivolumab (BMS-936558)
Nivolumab (BMS-936558) Intravenous solution every 2 weeks
Drug: Nivolumab (BMS-936558)



Primary Outcome Measures :
  1. Rate and frequency for high-grade (CTCAE v4.0 Grade 3 or higher) treatment-related, select adverse events in subjects with melanoma [ Time Frame: Safety assessments for approximately 2 years ]
  2. Rate and frequency of AEs regardless of causality [ Time Frame: Safety assessments for approximately 2 years ]
  3. Rate and frequency of treatment-related AEs [ Time Frame: Safety assessments for approximately 2 years ]
  4. Rate and frequency of any AEs of special interest (AEOSI), such as pulmonary, gastrointestinal, cuteaneous, renal, hepatic, pancreatic, endocrine, infusion-related, or hypersensitivity [ Time Frame: Safety assessments for approximately 2 years ]

Secondary Outcome Measures :
  1. Incidence of all high-grade (Grade 3 and higher) select adverse events [ Time Frame: approximately 2 years ]
  2. Median time to onset (Grades 3-4) of select adverse events [ Time Frame: approximately 2 years ]
  3. Median time to resolution (Grades 3-4) of select adverse events [ Time Frame: approximately 2 years ]
  4. Time to overall survival (OS) [ Time Frame: Survival status every couple of weeks for up to approximately 2 years, until death, lost to follow-up, or withdrawal of study consent ]
  5. Investigator assessed objective response rate (ORR) [ Time Frame: approximately 2 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

  • Subjects with histologically confirmed malignant melanoma
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS):

    • PS 0 to 1
    • PS 2
  • Previously treated unresectable stage III or stage IV melanoma as per the American Joint Committee on Cancer 2010 Guidelines regardless of BRAF mutation status
  • Subjects must have experienced evaluable Response Evaluation Criteria In Solid Tumors (RECIST 1.1)-defined disease progression
  • Prior treatment with chemotherapy, interferon (adjuvant setting), Interleukin (IL-2), BRAF/MEK inhibitors for subjects with known BRAF mutations, Mitogen-activated or extracellular signal- regulated protein kinase (MEK) inhibitors for Neuroblastoma Ras Viral (v-ras) oncogene homolog (NRAS) mutations, and cKIT inhibitor subjects with known cKIT mutations are allowed
  • Patients with CNS metastases are eligible:

    • if CNS metastases are treated, patients are asymptomatic or neurologically returned to baseline
    • if they have previously untreated CNS metastases and are asymptomatic
    • if they have leptomeningeal metastases, are treated and asymptomatic or neurologically returned to baseline with life expectancy > 3 months
  • Patients with a known history of Grades 3-4 immune-related adverse reactions during/after anti-CTLA-4 therapy if all toxicities have resolved at least to Grade 1

Exclusion Criteria:

  • Subjects with untreated, active Central Nervous System (CNS) metastases are excluded

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02156804


  Hide Study Locations
Locations
Layout table for location information
Austria
Local Institution
Graz, Austria, 803 6
Local Institution
Innsbruck, Austria, 6020
Local Institution
Salzburg, Austria, 5020
Local Institution
St. Polten, Austria, 3100
Local Institution
Wien, Austria, 1030
Local Institution
Wien, Austria, 1090
Belgium
Universitair Ziekenhuis Brussel
Brussels, Belgium, 1090
Institut Jules Bordet
Bruxelles, Belgium, 1000
Cliniques Universitaires Saint-Luc
Bruxelles, Belgium, 1200
Local Institution
Edegem, Belgium, 2650
Local Institution
Gent, Belgium, 9000
Local Institution
Hasselt, Belgium, 3500
Az Groeninge
Kortrijk, Belgium, 8500
Local Institution
Leuven, Belgium, 3000
Chu De Liege
Liege, Belgium, 4000
Czechia
Local Institution
Brno, Czechia, 656 53
Local Institution
Hradec Kralove, Czechia, 500 05
Local Institution
Praha 10, Czechia, 100 34
Local Institution
Praha 2, Czechia, 120 28
Finland
Local Institution
Helsinki, Finland, 00290
Local Institution
Jyvaskyla, Finland, 40620
Local Institution
Oulu, Finland, 90220
Local Institution
Tampere, Finland, 33520
Germany
Local Institution
Luebeck, Schleswig-holstein, Germany, 23538
Local Institution
Augsburg, Germany, 86156
Local Institution
Bochum, Germany, 44791
Local Institution
Buxtehude, Germany, 21614
Local Institution
Chemnitz, Germany, 09117
Local Institution
Dessau, Germany, 06847
Local Institution
Dresden, Germany, 01307
Local Institution
Erfurt, Germany, 99089
Local Institution
Erlangen, Germany, 91054
Local Institution
Essen, Germany, 45 122
Local Institution
Frankfurt Am Main, Germany, 60590
Local Institution
Freiburg, Germany, 79104
Local Institution
Gera, Germany, 07548
Local Institution
Giessen, Germany, 35385
Local Institution
Goettingen, Germany, 37075
Local Institution
Hamburg, Germany, 20253
Local Institution
Hannover, Germany, 30625
Local Institution
Heidelberg, Germany, 69120
Local Institution
Heilbronn, Germany, 74078
Local Institution
Jena, Germany, 07740
Local Institution
Kassel, Germany, 34125
Local Institution
Kiel, Germany, 24105
Local Institution
Koln, Germany, 50937
Local Institution
Leipzig, Germany, 04103
Local Institution
Ludwigshafen, Germany, 67063
Local Institution
Magdeburg, Germany, 39120
Local Institution
Mainz, Germany, 55131
Local Institution
Marburg, Germany, 35043
Local Institution
Minden, Germany, 32429
Local Institution
Muenster, Germany, 48149
Local Institution
Munchen, Germany, 81675
Local Institution
Munich, Germany, 80337
Local Institution
Munster, Germany, 48157
Local Institution
Nuernberg, Germany, 90419
Local Institution
Quedlinburg, Germany, 06484
Local Institution
Recklinghausen, Germany, 45657
Local Institution
Regensburg, Germany, 93053
Local Institution
Schwerin, Germany, 19049
Local Institution
Traunstein, Germany, 83278
Local Institution
Tubingen, Germany, 72076
Local Institution
Wurzbug, Germany, 97080
Greece
Local Institution
Heraklion, Creta, Greece, 71201
Local Institution
Athens, Greece, 11527
Local Institution
Athens, Greece, 18547
Local Institution
Thessaloniki, Greece, 54007
Local Institution
Thessaloniki, Greece, 57010
Hungary
Local Institution
Budapest, Hungary, 1122
Local Institution
Budapest, Hungary, H-7085
Local Institution
Debrecen, Hungary, 4032
Local Institution
Pecs, Hungary, H-7632
Local Institution
Szegedi, Hungary, 6720
Local Institution
Szombathely, Hungary, 9700
Ireland
Local Institution
Wilton, Cork, Ireland
Local Institution
Dublin, Ireland, 4
Local Institution
Dublin, Ireland, 7
Local Institution
Dublin, Ireland, 8
Local Institution
Dublin, Ireland, 9
Local Institution
Galway, Ireland
Local Institution
Waterford, Ireland, 9026
Italy
Local Institution
Bari, Italy, 70124
Local Institution
Bergamo, Italy, 24127
Local Institution
Genova, Italy, 16132
Local Institution
Meldola (FC), Italy, 47014
Local Institution
Milano, Italy, 20132
Local Institution
Milano, Italy, 20133
Local Institution
Milano, Italy, 20141
Local Institution
Napoli, Italy, 80131
Local Institution
Padova, Italy, 35128
Local Institution
Palermo, Italy, 90127
Local Institution
Roma, Italy, 00144
Local Institution
Roma, Italy, 00167
Local Institution
Siena, Italy, 53100
Local Institution
Terni, Italy, 05100
Local Institution
Torino, Italy, 10137
Luxembourg
Local Institution
Luxembourg, Luxembourg, 1210
Netherlands
Local Institution
Amsterdam, Netherlands, 1066 CX
Local Institution
Amsterdam, Netherlands, 1081 HZ
Local Institution
Breda, Netherlands, 4918 EV
Local Institution
Enschede, Netherlands, 7513 ER
Local Institution
Groningen, Netherlands, 9713 GZ
Local Institution
Leeuwarden, Netherlands, 8901 BR
Local Institution
Leiden, Netherlands, 2300 RC
Local Institution
Maastrict, Netherlands, 6229 HX
Local Institution
Nijmegen, Netherlands, 6525 GA
Local Institution
Rotterdam, Netherlands, 3075 EA
Local Institution
Sittard-Geleen, Netherlands, 6162 BG
Local Institution
Utrecht, Netherlands, 3584 CX
Local Institution
Veldhoven, Netherlands, 5504 DB
Local Institution
Zwolle, Netherlands, 8025-AB
Norway
Local Institution
Alesund, Norway, 6017
Local Institution
Bergen, Norway, 5021
Local Institution
Oslo, Norway, 0310
Poland
Local Institution
Bydgoszcz, Poland, 85-796
Local Institution
Gdansk, Poland, 80-952
Local Institution
Lodz, Poland, 93513
Local Institution
Warszawa, Poland, 02781
Portugal
Local Institution
Coimbra, Portugal, P-3050-075
Local Institution
Lisboa, Portugal, 1099-023
Local Institution
Porto, Portugal, 4200-072
Romania
Local Institution
Bucharest, Romania, 022328
Local Institution
Romania, Romania, 400015
Russian Federation
Local Institution
Moscow, Russian Federation, 115478
Local Institution
St. Petersburg, Russian Federation, 197022
Local Institution
St. Petersburg, Russian Federation, 197758
Spain
Local Institution
Albacete, Spain, 02006
Local Institution
Barcelona, Spain, 08035
Local Institution
Barcelona, Spain, 08036
Local Institution
Barcelona, Spain, 08908
Local Institution
Bilbao, Spain, 48013
Local Institution
Granada, Spain, 18014
Local Institution
Las Palmas de Gran Canaria, Spain, 35016
Local Institution
Madrid, Spain, 28007
Local Institution
Madrid, Spain, 28041
Local Institution
Madrid, Spain, 28046
Hospital De Madrid, Norte Sanchinarro
Madrid, Spain, 28050
Local Institution
Malaga, Spain, 29010
Local Institution
Oviedo, Spain, 33011
Local Institution
Palma de Mallorca, Spain, 07010
Local Institution
Salamanca, Spain, 37007
Local Institution
San Sebastian, Spain, 20014
Comp. H. U. De Santiago
Santiago de Compostela, Spain, 15706
Local Institution
Sevilla, Spain, 41071
Local Institution
Toledo, Spain, 45071
Local Institution
Valencia, Spain, 46009
Local Institution
Valencia, Spain, 46026
Sweden
Local Institution
Lund, Sweden, 221 85
Local Institution
Uppsala, Sweden, 751 85
Switzerland
Local Institution
Aarau, Switzerland, 5001
Local Institution
Basel, Switzerland, 4031
Local Institution
Bellinzona, Switzerland, 6501
Local Institution
Bern, Switzerland, 3010
Local Institution
Chur, Switzerland, 7000
Local Institution
Zurich, Switzerland, 8091
United Kingdom
Local Institution
Bristol, Avon, United Kingdom, BS2 8ED
Local Institution
Northwood, Middlesex, United Kingdom, HA6 2RN
Local Institution
Birmingham, United Kingdom, B15 2TH
Local Institution
Cambridge, United Kingdom, CB2 0QQ
Local Institution
Cottingham, United Kingdom, HU16 5JQ
Local Institution
Essex, United Kingdom
Local Institution
Glasgow, United Kingdom, G12 0YN
Local Institution
London, United Kingdom, SE1 9RT
Local Institution
Manchester, United Kingdom, M20 4BX
Local Institution
Newcastle Upon Tyne, United Kingdom, NE7 7DN
Local Institution
Oxford, United Kingdom, OX3 7LE
Local Institution
Southampton, United Kingdom, SO16 6YD
Local Institution
Surrey, United Kingdom, SM2 5PT
Local Institution
Swansea, United Kingdom, SA2 8QA
Local Institution
Truro, United Kingdom, TR1 3LJ
Local Institution
Wirral, United Kingdom, CH63 4JY
Sponsors and Collaborators
Bristol-Myers Squibb
Investigators
Layout table for investigator information
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb

Additional Information:
Layout table for additonal information
Responsible Party: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT02156804     History of Changes
Other Study ID Numbers: CA209-172
2014-001286-28 ( EudraCT Number )
First Posted: June 5, 2014    Key Record Dates
Last Update Posted: July 13, 2018
Last Verified: July 2018

Additional relevant MeSH terms:
Layout table for MeSH terms
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas
Antibodies
Antibodies, Monoclonal
Nivolumab
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents, Immunological
Antineoplastic Agents